JCR Pharmaceuticals | Evaluate

Go or no go? Biogen and Astellas head towards key Pdufas

February 10, 2021

World Symposium – Orchard leads the crop of Hurler syndrome hopefuls

Promising early data with the group’s gene therapy put it ahead of Regenxbio for now.

October 02, 2020

Mesoblast can’t catch a break

November 01, 2019

Upcoming events – key tests approach for Kadmon and Surface

Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.

November 24, 2017

Upcoming events – Another SGLT2 approval due and stem cell data for Mesoblast

April 08, 2013

Japan dominates small cap stock price rises in Q1

July 19, 2012

Event – Glaxo endorsement puts focus on Amicus phase III result and more

October 13, 2010

Glaxo attracted to rare diseases